Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Conditions:   Pancreatic Cancer;   Small Bowel Cancer;   Colorectal Cancer;   Melanoma;   Non Small Cell Lung Cancer;   Thyroid Cancer;   Bladder Cancer;   Head and Neck Cancer;   Gastric Cancer;   Esophageal Cancer;   Cholangiocarcinoma;   Ovarian Cancer;   Hepatocellular Carcinoma;   Glioblastoma;   MAPK Gene Mutation;   KRAS Activating Mutation;   BRAF Gene Mutation;   NRAS Gene Mutation;   HRAS Gene Mutation;   MEK Mutation;   ERK Mutation
Intervention:   Drug: Ulixertinib (BVD-523)
Sponsors:   xCures;   Cancer Commons
Available

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 29, 2020 / by / in
Comments